Literature DB >> 11474499

Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.

J Chia-Hsien Cheng1, V P Chuang, S H Cheng, Y M Lin, T I Cheng, P S Yang, J J Jian, D L You, C F Horng, A T Huang.   

Abstract

The purpose of our study was to evaluate the outcome, patterns of failure, and toxicity for patients with unresectable hepatocellular carcinoma (HCC) treated with radiotherapy, transcatheter arterial chemoembolization (TACE), or combined TACE and radiotherapy. Forty-two patients with unresectable HCC were treated with combined radiotherapy and TACE (TACE+RT group, 17 patients), radiotherapy alone (RT group, 9 patients), or with TACE alone (TACE group, 16 patients). Mean dose of radiation was 46.9 +/- 5.8 Gy in a daily fraction of 1.8 to 2 Gy, directed only to the cancer-involved areas of the liver. TACE was performed with a combination of Lipiodol, doxorubicin, cisplatin, and mitomycin C, followed by Gelfoam or Ivalon embolization. Tumor size was smaller in the TACE group (mean: 5.4 cm) compared with the TACE+RT group (8.6 cm) and the RT group (13.1 cm) (P = 0.0003). The median follow-up was 24 months in the TACE+RT group, 28 months in the RT group, and 23 months in the TACE group. Survival was significantly worse for patients treated with radiotherapy alone due to the selection bias of patients with more advanced disease and compromised condition in this group. In contrast, the TACE+RT and TACE groups had comparable survival (two-year rates: TACE+RT 58%, TACE 56%, P = 0.69). The local control rate for the treated tumors was similar in the TACE+RT and TACE groups (P = 0.11). The intrahepatic recurrence outside the treated tumors was common and similar between these two groups (P = 0.48). The extrahepatic progression-free survival was significantly shorter for patients in the TACE+RT group than in the TACE group (two-year rates: TACE+RT 36%, TACE 100%, P = 0.002). Seven patients died from complications of treatment. Local radiotherapy may be added to treat patients with unresectable HCC, and the control of progression of the treated tumors was promising even in patients with large hepatic tumors. Survival of patients with combined TACE and radiotherapy was similar to that with TACE as the only treatment, while a significant portion of the patients treated with radiotherapy developed extrahepatic metastasis. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474499     DOI: 10.1002/ijc.1022

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Enhancement of leukocyte adhesion after percutaneous irradiation in rats with hepatocellular carcinoma.

Authors:  Sasa-Marcel Maksan; Eduard Schmidt; Eduard Ryschich; Wolfgang Harms; Jan Schmidt
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

2.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Authors:  Roderich E Schwarz; Ghassan K Abou-Alfa; Jeffrey F Geschwind; Sunil Krishnan; Riad Salem; Alan P Venook
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 3.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 4.  Liver embolizations in oncology. A review. Part II. Arterial radioembolizations, portal venous embolizations, experimental arterial embolization procedures.

Authors:  Peter Gunvén
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 5.  3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  Li-Qun Zou; Bing-Lan Zhang; Qing Chang; Fu-Ping Zhu; Yan-Yan Li; Yu-Quan Wei; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

6.  Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat.

Authors:  Sasa-Marcel Maksan; Patrick Morad Araib; Eduard Ryschich; Martha Maria Gebhard; Jan Schmidt
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

7.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  De-Hua Wu; Li Liu; Long-Hua Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 8.  Challenge and hope in radiotherapy of hepatocellular carcinoma.

Authors:  Jinsil Seong
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

9.  Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas.

Authors:  Xiao-Ping Li; Zhen Chen; Zhi-Qiang Meng; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.